CHINA SXT PHARMACEUTICALS IN SXTC
USD CL A ORD SHS · Common Stock · CUSIP G2161P165
- SectorHealth care
- IndustryPharmaceutical Preparations
- FilingsSEC EDGAR
3
institutional holders
-1 vs Q1 2026
16
shares reported held*
$6reported value*
0 new
1 added
0 reduced
1 sold out
net sold ≈ $131.3k (-78.2k shares)
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $0.38.
Trends to Q2 2026
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q1 2026 | 4 |
| Q2 2026 | 3 |
Biggest buyers
Biggest sellers
| SABBY MANAGEMENT, LLC | Sold out | -78.2k |
Insider purchases and sales since 1 Apr 2026
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
None reported since 1 Apr 2026.
Holders, Q2 2026
| Manager | Shares | Change |
|---|---|---|
| ROYAL BANK OF CANADA 0.00% of their portfolio | 13 $0 | Unchanged |
| Caitong International Asset Management Co., Ltd 0.00% of their portfolio | 2 $4 | Added +1 |
| UBS Group AG 0.00% of their portfolio | 1 $2 | Unchanged |